

Matti Annala

List of Publications by Year in descending order

Source: <https://exaly.com/author-pdf/1666843/publications.pdf>

Version: 2024-02-01

37
papers

6,140
citations

304602

22
h-index

315616

38
g-index

39
all docs

39
docs citations

39
times ranked

10303
citing authors

#	ARTICLE	IF	CITATIONS
1	Somatic Features of Response and Relapse in Non-muscle-invasive Bladder Cancer Treated with Bacillus Calmette-Guérin Immunotherapy. <i>European Urology</i> , 2022, 5, 677-686.	2.6	6
2	Genomic Features of Lung-Recurrent Hormone-Sensitive Prostate Cancer. <i>JCO Precision Oncology</i> , 2022, 6, e2100543.	1.5	7
3	<i>BRCA2</i> , <i>ATM</i> , and <i>CDK12</i> Defects Differentially Shape Prostate Tumor Driver Genomics and Clinical Aggression. <i>Clinical Cancer Research</i> , 2021, 27, 1650-1662.	3.2	52
4	Evolution of Castration-Resistant Prostate Cancer in ctDNA during Sequential Androgen Receptor Pathway Inhibition. <i>Clinical Cancer Research</i> , 2021, 27, 4610-4623.	3.2	41
5	Plasma ctDNA is a tumor tissue surrogate and enables clinical-genomic stratification of metastatic bladder cancer. <i>Nature Communications</i> , 2021, 12, 184.	5.8	85
6	Plasma Circulating Tumor DNA and Clonal Hematopoiesis in Metastatic Renal Cell Carcinoma. <i>Clinical Genitourinary Cancer</i> , 2020, 18, 322-331.e2.	0.9	30
7	AR and ERG drive the expression of prostate cancer specific long noncoding RNAs. <i>Oncogene</i> , 2020, 39, 5241-5251.	2.6	4
8	Activating <i>AKT1</i> and <i>PIK3CA</i> Mutations in Metastatic Castration-Resistant Prostate Cancer. <i>European Urology</i> , 2020, 78, 834-844.	0.9	47
9	Moderate-to-strong expression of <i>FGFR3</i> and <i>TP53</i> alterations in a subpopulation of choroid plexus tumors. <i>Histology and Histopathology</i> , 2020, 35, 673-680.	0.5	3
10	Morphologic and genomic characterization of urothelial to sarcomatoid transition in muscle-invasive bladder cancer. <i>Urologic Oncology: Seminars and Original Investigations</i> , 2019, 37, 573.e19-573.e29.	0.8	13
11	Optimal sequencing of enzalutamide and abiraterone acetate plus prednisone in metastatic castration-resistant prostate cancer: a multicentre, randomised, open-label, phase 2, crossover trial. <i>Lancet Oncology</i> , 2019, 20, 1730-1739.	5.1	227
12	Morphologic and genomic characterization of urothelial to sarcomatoid transition in muscle-invasive bladder cancer. <i>Urologic Oncology: Seminars and Original Investigations</i> , 2019, 37, 826-836.	0.8	33
13	Evaluation of Commercial Circulating Tumor DNA Test in Metastatic Prostate Cancer. <i>JCO Precision Oncology</i> , 2019, 3, 1-9.	1.5	26
14	Circulating Tumor DNA Abundance and Potential Utility in De Novo Metastatic Prostate Cancer. <i>European Urology</i> , 2019, 75, 667-675.	0.9	131
15	Circulating Tumor DNA Genomics Correlate with Resistance to Abiraterone and Enzalutamide in Prostate Cancer. <i>Cancer Discovery</i> , 2018, 8, 444-457.	7.7	376
16	Whole-exome sequencing identifies germline mutation in <i>TP53</i> and <i>ATRX</i> in a child with genomically aberrant AT/RT and her mother with anaplastic astrocytoma. <i>Journal of Physical Education and Sports Management</i> , 2018, 4, a002246.	0.5	5
17	Integrative proteomics in prostate cancer uncovers robustness against genomic and transcriptomic aberrations during disease progression. <i>Nature Communications</i> , 2018, 9, 1176.	5.8	117
18	Frequent mutation of the <i>FOXA1</i> untranslated region in prostate cancer. <i>Communications Biology</i> , 2018, 1, 122.	2.0	21

#	ARTICLE	IF	CITATIONS
19	Constitutively active androgen receptor splice variants AR-V3, AR-V7 and AR-V9 are co-expressed in castration-resistant prostate cancer metastases. <i>British Journal of Cancer</i> , 2018, 119, 347-356.	2.9	63
20	Molecular Dissection of Complete Response to Receptor Tyrosine Kinase Inhibition in Type II Papillary Renal Cell Carcinoma. <i>Clinical Genitourinary Cancer</i> , 2017, 15, e145-e150.	0.9	1
21	Treatment Outcomes and Tumor Loss of Heterozygosity in Germline DNA Repair-deficient Prostate Cancer. <i>European Urology</i> , 2017, 72, 34-42.	0.9	179
22	Impact of Therapy on Genomics and Transcriptomics in High-Risk Prostate Cancer Treated with Neoadjuvant Docetaxel and Androgen Deprivation Therapy. <i>Clinical Cancer Research</i> , 2017, 23, 6802-6811.	3.2	69
23	Circulating Tumor DNA Reveals Clinically Actionable Somatic Genome of Metastatic Bladder Cancer. <i>Clinical Cancer Research</i> , 2017, 23, 6487-6497.	3.2	121
24	Segmentum: a tool for copy number analysis of cancer genomes. <i>BMC Bioinformatics</i> , 2017, 18, 215.	1.2	7
25	Concordance of Circulating Tumor DNA and Matched Metastatic Tissue Biopsy in Prostate Cancer. <i>Journal of the National Cancer Institute</i> , 2017, 109, .	3.0	288
26	The expression of AURKA is androgen regulated in castration-resistant prostate cancer. <i>Scientific Reports</i> , 2017, 7, 17978.	1.6	38
27	OUP accepted manuscript. <i>Neuro-Oncology</i> , 2017, 19, 1206-1216.	0.6	17
28	Microseminoprotein-Beta Expression in Different Stages of Prostate Cancer. <i>PLoS ONE</i> , 2016, 11, e0150241.	1.1	28
29	Integrated clinical, whole-genome, and transcriptome analysis of multisampled lethal metastatic prostate cancer. <i>Journal of Physical Education and Sports Management</i> , 2016, 2, a000752.	0.5	24
30	Genomic Alterations in Cell-Free DNA and Enzalutamide Resistance in Castration-Resistant Prostate Cancer. <i>JAMA Oncology</i> , 2016, 2, 1598.	3.4	290
31	Moving Toward Personalized Care: Liquid Biopsy Predicts Response to Cisplatin in an Unusual Case of BRCA2-Null Neuroendocrine Prostate Cancer. <i>Clinical Genitourinary Cancer</i> , 2016, 14, e233-e236.	0.9	15
32	Epigenetically altered miR-193b targets cyclin D1 in prostate cancer. <i>Cancer Medicine</i> , 2015, 4, 1417-1425.	1.3	39
33	The evolutionary history of lethal metastatic prostate cancer. <i>Nature</i> , 2015, 520, 353-357.	13.7	1,185
34	The Molecular Taxonomy of Primary Prostate Cancer. <i>Cell</i> , 2015, 163, 1011-1025.	13.5	2,435
35	Transcriptome Sequencing Reveals PCAT5 as a Novel ERG-Regulated Long Noncoding RNA in Prostate Cancer. <i>Cancer Research</i> , 2015, 75, 4026-4031.	0.4	68
36	Recurrent SKIL-activating rearrangements in ETS-negative prostate cancer. <i>Oncotarget</i> , 2015, 6, 6235-6250.	0.8	23

#	ARTICLE	IF	CITATIONS
37	DOT1L-HES6 fusion drives androgen independent growth in prostate cancer. EMBO Molecular Medicine, 2014, 6, 1121-1123.	3.3	17